logo
episode-header-image
Oct 2023
23m 2s

S1 Episode 6: Systemic Therapy for Advan...

MEDSCAPE
About this episode

Join experts Drs Benjamin Schlechter and Diane Saverese as they discuss systemic therapy for advanced colorectal cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988974). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Characterization of Two Metastatic Subpopulations Originating From a Single Human Colon Carcinoma https://pubmed.ncbi.nlm.nih.gov/6861147/

The Phenomenon of Pleiotropic Drug Resistance https://pubmed.ncbi.nlm.nih.gov/3331384/

Early Memories of Burton "Bud" Rose, Founder of UpToDate — and Medical Education Visionary https://blogs.jwatch.org/hiv-id-observations/index.php/early-memories-of-burton-bud-rose-founder-of-uptodate-and-medical-education-visionary/2020/05/06/

Combining Chemotherapy and Targeted Therapies in Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/17990352/

Addition of Cetuximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 MRC COIN Trial https://pubmed.ncbi.nlm.nih.gov/21641636/

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? https://pubmed.ncbi.nlm.nih.gov/28214977/

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) https://pubmed.ncbi.nlm.nih.gov/30552157/

FOLFOXIRI Plus Bevacizumab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment of Patients With Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study https://pubmed.ncbi.nlm.nih.gov/26338525/

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/23881988/

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/19339720/

Final Results From PRIME: Randomized Phase III Study of Panitumumab With FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/24718886/

FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer: Final Survival and Per-Protocol Analysis of FIRE-3, A Randomised Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33154570/

FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25088940/

Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong? https://pubmed.ncbi.nlm.nih.gov/30545999/

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/34061178/

Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA Collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/33271092/

Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) https://pubmed.ncbi.nlm.nih.gov/30688523/

The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials https://pubmed.ncbi.nlm.nih.gov/31855256/

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial https://pubmed.ncbi.nlm.nih.gov/34516759/

Up next
Sep 2024
S2 Episode 6: In Colorectal Cancer, Donating Half a Liver Could Save Lives
Join Drs Benjamin Schlechter and Martin Dib as they discuss cutting-edge transplant techniques to treat colorectal cancer. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1000094. The topics and discussions are planne ... Show More
26m 25s
Aug 2024
S2 Episode 5: Adjuvant Chemo in Colorectal Cancer: What's Working Now?
Join Drs Benjamin Schlechter and Jeff Meyerhardt as they discuss the latest breakthroughs in adjuvant chemo for CRC and share their decision-making in real-world scenarios. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarti ... Show More
24m 52s
Jul 2024
S2 Episode 4: The Evolution of Nonoperative Rectal Cancer Management
Join Drs Benjamin Schlechter and Joshua Smith as they discuss the evolution of nonoperative rectal cancer management and organ preservation, highlighting groundbreaking trials like OPRA and JANUS. Relevant disclosures can be found with the episode show notes on Medscape https://w ... Show More
26m 27s
Recommended Episodes
Nov 2023
Hereditary Breast Cancer, Genetic Testing, and Therapeutic Implications
Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991258). The topics and discussions ... Show More
19m 26s
Oct 2022
Treatment of Metastatic Colorectal Cancer Guideline
An interview with Dr. Van Morris from The University of Texas MD Anderson Cancer Center in Houston, TX and Dr. Cathy Eng from Vanderbilt-Ingram Cancer Center in Nashville, TN, co-chairs on "Treatment of Metastatic Colorectal Cancer: ASCO Guideline." Dr. Morris and Dr. Eng review ... Show More
21m 12s
Dec 2023
Thinking Beyond TROP2 at ESMO 2023
What were the biggest takeaways from ESMO 2023 related to TNBC and IBC? Tune in to hear experts Drs Kevin Kalinsky and Filipa Lynce discuss. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991259). The topics and dis ... Show More
17m 6s
Dec 2022
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline
Dr. Emrullah Yilmaz reviews the latest evidence and recommendations for health care providers on biomarker testing and immunotherapy for head and neck cancers. He discusses the ASCO Expert Panel’s recommendations for biomarkers for the selection of patients with head and neck squ ... Show More
13m 51s
Jun 2022
Biomarkers for Systemic Therapy in Metastatic Breast Cancer Guideline Update
An interview with Dr. Lynn Henry from the University of Michigan in Ann Arbor, MI, lead author on "Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update." Dr. Henry reviews new biomarkers for the purposes of making treatment decisions for triple-negat ... Show More
15m 29s
Jun 2022
Systemic Therapy for Melanoma Rapid Recommendation Update
An interview with Dr. Pauline Funchain from Cleveland Clinic in Cleveland, OH, author on "Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update." Dr. Funchain reviews recent evidence and updated recommendations from the ASCO Expert Panel for the use of tebenta ... Show More
7m 50s
Jan 2023
Targeted Therapy and Immunotherapy for Gastroesophageal Cancer Guideline
Dr. Manish Shah discusses the first ASCO guideline for advanced gastroesophageal cancer. He addresses biomarker testing to help guide therapy - including HER2 testing, mismatch repair testing, and assessment of PD-L1 expression. Dr. Shah then reviews the evidence-based recommenda ... Show More
13m 32s
Aug 2023
#267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this e ... Show More
1h 50m
Mar 2024
Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show More
14m 9s
Oct 2023
Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline
Dr. Greg Kalemkerian joins us on the ASCO Guideline Podcast to discuss the newest ASCO – Ontario Health (Cancer Care Ontario) Guideline on systemic therapy for small-cell lung cancer (SCLC). He reviews the evidence-based recommendations from the panel, including guidance on syste ... Show More
27m 13s